424B3 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)

424B3 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)

8-K - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)

8-K - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)

8-K - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)

424B3 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)

EFFECT - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)

DEF 14A - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)

S-1 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)

10-Q - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)

4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

3 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

SC 13G - Coeptis Therapeutics Holdings, Inc. (0001759186) (Subject)

SC 13G/A - Coeptis Therapeutics Holdings, Inc. (0001759186) (Subject)

SC 13D - Coeptis Therapeutics Holdings, Inc. (0001759186) (Subject)

SC 13G/A - Coeptis Therapeutics Holdings, Inc. (0001759186) (Subject)

SC 13G/A - Coeptis Therapeutics Holdings, Inc. (0001759186) (Subject)

SC 13G/A - Bull Horn Holdings Corp. (0001759186) (Subject)

SC 13G - Bull Horn Holdings Corp. (0001759186) (Subject)

SC 13G/A - Bull Horn Holdings Corp. (0001759186) (Subject)

SC 13G - Bull Horn Holdings Corp. (0001759186) (Subject)

SC 13G/A - Bull Horn Holdings Corp. (0001759186) (Subject)

Combined company to operate as Coeptis Therapeutics Holdings, Inc. and commence trading on The Nasdaq Global Market under Ticker Symbol "COEP" WEXFORD, Pa. and MIAMI, Oct. 31, 2022 /PRNewswire/ -- Coeptis Therapeutics, Inc. ("Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced the completion of its business combination with Bull Horn Holdings Corp. (NASDAQ:BHSE), a special purpose acquisition company ("Bull Horn").  In connection with the Business Combination, the combined company has been renamed "Coeptis Therapeutics Holdings, Inc." (the "Company") and its public shares and warrants are expected to commence trading on the Nasdaq G

SNAP-CAR therapy provides a highly programmable therapeutic platform designed to potentially target many tumor types, including hematological malignancies and solid tumors WEXFORD, Pa., Sept. 21, 2022 /PRNewswire/ -- Coeptis Therapeutics, Inc. (OTC:COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced entry into an exclusive license agreement with the University of Pittsburgh for the rights to a chimeric antigen receptor T cell (CAR T) technology – SNAP-CAR – designed to target multiple antigens simultaneously and potentially address a range of hematologic and solid tumors, including breast and ovarian cancer.

Option agreement comprises three technologies and associated patent portfolios Announcement marks the third strategic agreement for Coeptis this quarter designed to bolster its portfolio and complement its innovative cell therapy platforms WEXFORD, Pa., May 17, 2022 /PRNewswire/ -- Coeptis Therapeutics, Inc. (OTC:COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced entry into an exclusive option agreement with the University of Pittsburgh for the rights to three chimeric antigen receptor T cell (CAR-T) technologies that offer the potential to address a range of hematologic and solid tumors. Among the initial

NEW YORK, May 6, 2022 /PRNewswire/ -- Major Arena Soccer League today announced that Brazilian global football legend Ronaldo de Assis Moreira, affectionately known as Ronaldinho Gaúcho or simply Ronaldinho, is joining the world's best indoor league as a Co-Owner of an expansion team. The soccer icon brings worldwide attention to the Major Arena Soccer League, as his ownership reflects his love of the indoor game and pays tribute to his roots in futsal. Considered one of the best players of his generation and regarded by many as one of the greatest players of all time, Ronaldi

Transaction expected to accelerate Coeptis' ability to progress its innovative cell therapy platforms for cancer David Mehalick of Coeptis to serve as Chief Executive Officer; Chris Calise of Bull Horn to join the Board of Directors Merger anticipated to close in third quarter 2022; combined company anticipated to list on Nasdaq WEXFORD, Pa., and MIAMI, Fla., April 19, 2022 /PRNewswire/ -- Coeptis Therapeutics, Inc. (OTC:COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, and Bull Horn Holdings Corp. (NASDAQ:BHSE) ("Bull Horn"), a special purpose acquisition company (SPAC), today announced they have entered into a definitiv

Bull Horn Holdings Corp. (NASDAQ:BHSE) (the "Company") today announced that it has received a notice ("Notice") from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") as a result of its failure to file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2021 (the "Form 10-Q") in a timely fashion. The Notice advised the Company that it was not in compliance with Nasdaq's continued listing requirements under the timely filing criteria established in Nasdaq Listing Rule 5250(c)(1). As reported by the Company in its Form 12b-25 filed with the Securities and Exchange Commission (the "SEC") on August 16, 2021, the Company was unable to file its Form 10-Q wi

Bull Horn Holdings Corp. (NASDAQ:BHSE) (the "Company") today announced that it has received a notice ("Notice") from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") as a result of its failure to file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 (the "Form 10-Q") in a timely fashion. The Notice advised the Company that it was not in compliance with Nasdaq's continued listing requirements under the timely filing criteria established in Nasdaq Listing Rule 5250(c)(1). As reported by the Company in its Form 12b-25 filed with the Securities and Exchange Commission (the "SEC") on May 17, 2021, the Company was unable to file its Form 10-Q with

4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

Combined company to operate as Coeptis Therapeutics Holdings, Inc. and commence trading on The Nasdaq Global Market under Ticker Symbol "COEP" WEXFORD, Pa. and MIAMI, Oct. 31, 2022 /PRNewswire/ -- Coeptis Therapeutics, Inc. ("Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced the completion of its business combination with Bull Horn Holdings Corp. (NASDAQ:BHSE), a special purpose acquisition company ("Bull Horn").  In connection with the Business Combination, the combined company has been renamed "Coeptis Therapeutics Holdings, Inc." (the "Company") and its public shares and warrants are expected to commence trading on the Nasdaq

Gainers Quanergy Systems, Inc. (NASDAQ:QNGY) jumped 153.9% to close at $3.30 on Friday. Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) surged 61.4% to close at $0.92 after jumping 15% on Thursday. Nuvalent, Inc. (NASDAQ:NUVL) shares gained 60.6% to close at $35.34 after the company reported preliminary Phase 1 clinical data from the ARROS-1 trial that support the best-in-class potential of NVL-520 for patients with ROS1-positive NSCLC. Bull Horn Holdings Corp. (NASDAQ:BHSE) jumped 44.7% to close at $11.95. Fangdd Network Group Ltd. (NASDAQ:DUO) gained 36.6% to close at $1.94. Provident Acquisition Corp. (NASDAQ:PAQC) shares jumped 32.7% to close at $11.00. Perfect Corp. and Provident Ac

Gainers Quanergy Systems, Inc. (NASDAQ:QNGY) surged 179% to $3.6301. Nuvalent, Inc. (NASDAQ:NUVL) shares jumped 62% to $35.60 after the company reported preliminary Phase 1 clinical data from the ARROS-1 trial that support the best-in-class potential of NVL-520 for patients with ROS1-positive NSCLC. Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) climbed 38% to $0.7860 after jumping 15% on Thursday. Sierra Metals Inc. (NYSE:SMTS) gained 32% to $0.2201. Sierra Metals' largest shareholder and Compañia Minera Kolpa announced Letter of Intent for Sierra Metals transaction and financing. Rail Vision Ltd. (NASDAQ:RVSN) jumped 31.6% to $0.7899. Agrify Corporation (NASDAQ:AGFY) surged 31% to $2.1

Option agreement comprises three technologies and associated patent portfolios Announcement marks the third strategic agreement for Coeptis this quarter designed to bolster its portfolio and complement its innovative cell therapy platforms WEXFORD, Pa., May 17, 2022 /PRNewswire/ -- Coeptis Therapeutics, Inc. (OTC:COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced entry into an exclusive option agreement with the University of Pittsburgh for the rights to three chimeric antigen receptor T cell (CAR-T) technologies that offer the potential to address a range of hematologic and solid tumors. Among the initia

Coeptis Therapeutics Inc (OTC:COEP) has agreed to a $175 million merger deal with Bull Horn Holdings Corporation (NASDAQ:BHSE), a special purpose acquisition company. Upon completing the deal, Bull Horn will be rebranded and operate as Coeptis Therapeutics Holdings Inc. and is expected to be listed on Nasdaq under the ticker symbol COEP. With this transaction, expected to be completed in the third quarter, the shareholders of Coeptis will receive equity in Bull Horn valued at $175 million. Related: Coeptis Therapeutics Intends To Acquire Statera's TLR5 Agonist Platform. The merger is anticipated to push Coeptis' efforts to boost its cell therapy platforms to treat cancer. Coeptis is a

    On Thursday, 75 stocks made new 52-week highs. Interesting Highlights From Today's 52-Week Lows: The largest company by market cap to hit a new 52-week high was UnitedHealth Group (NYSE:UNH). The smallest company in terms of market cap to set a new 52-week high was China Jo-Jo Drugstores (NASDAQ:CJJD). China Jo-Jo Drugstores (NASDAQ:CJJD) was the biggest winner of the morning session, as it traded up 1123.11% to reach its new 52-week high. Blue Ocean Acquisition (NASDAQ:BOCN) shares suffered the most, as they hit a 52-week high but moved 0.0% down thereafter. The following stocks created new 52-week highs on Thursday: UnitedHealth Group (NYSE:UNH) shares were up 0.61% on Th

Ownership of sports teams has often been limited to the wealthy or family members who inherited the team. A handful of sports teams are publicly traded, offering investors the opportunity to buy shares in the company. A handful of sales have happened across the four major U.S. sports over the last year. Two more teams are potentially on the block. Could a SPAC targeting the sports industry and team ownership land a stake in a professional sports team? Sports Teams For Sale: Among the newest sports teams put up for sale are the Toronto Blue Jays of Major League Baseball and the Denver Broncos of the National Football League. A sale of the Toronto Blue Jays could be put on hold given the l